Cargando…

Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease course. The recent advancement of antifibrotic therapy has increased the need for reliable and specific biomarkers. This study aimed to assess alveolar epithelial biomarkers as predictors for the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikeda, Kimiyuki, Chiba, Hirofumi, Nishikiori, Hirotaka, Azuma, Arata, Kondoh, Yasuhiro, Ogura, Takashi, Taguchi, Yoshio, Ebina, Masahito, Sakaguchi, Hiroki, Miyazawa, Shogo, Suga, Moritaka, Sugiyama, Yukihiko, Nukiwa, Toshihiro, Kudoh, Shoji, Takahashi, Hiroki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706186/ https://www.ncbi.nlm.nih.gov/pubmed/33256760 http://dx.doi.org/10.1186/s12931-020-01582-y

Ejemplares similares

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial
por: Taniguchi, Hiroyuki, et al.
Publicado: (2011)

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment
por: Azuma, Arata, et al.
Publicado: (2011)

Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020)

Transcription repressor Bach2 is required for pulmonary surfactant homeostasis and alveolar macrophage function
por: Nakamura, Atsushi, et al.
Publicado: (2013)

Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020)

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
por: Ogura, Takashi, et al.
Publicado: (2023)

Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia – short term evaluation of safety and tolerability
por: Kamio, Koichiro, et al.
Publicado: (2014)

Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2014)

Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage
por: Shioya, Makoto, et al.
Publicado: (2018)

Programmed Death-Ligand 1-Positive Squamous Cell Carcinoma Spontaneously Regressed after Percutaneous Needle Biopsy
por: Sasahara, Masayuki, et al.
Publicado: (2023)

A Case of Cutaneous Infection Caused by Mycobacterium Szulgai with Progression to Acute Respiratory Distress Syndrome
por: Ohta, Hiromitsu, et al.
Publicado: (2011)

Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis
por: Nishikiori, Hirotaka, et al.
Publicado: (2014)

Analysis of real-world data and a mouse model indicates that pirfenidone causes pellagra
por: Kuronuma, Koji, et al.
Publicado: (2022)

A Normal Range of KL-6/MUC1 Independent of Elevated SP-D Indicates a Better Prognosis in the Patients with Honeycombing on High-Resolution Computed Tomography
por: Hisata, Shu, et al.
Publicado: (2011)

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
por: Cottin, Vincent, et al.
Publicado: (2018)

Primary ciliary dyskinesia caused by a large homozygous deletion including exons 1–4 of DRC1 in Japanese patients with recurrent sinopulmonary infection
por: Keicho, Naoto, et al.
Publicado: (2019)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan
por: Minegishi, Yuji, et al.
Publicado: (2020)

Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies
por: Behr, Jürgen, et al.
Publicado: (2023)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Autoimmune Pulmonary Alveolar Proteinosis Diagnosed after Exposure to a Fire Extinguisher Containing Silica Powder
por: Yorozuya, Takafumi, et al.
Publicado: (2019)

Deep-learning algorithm to detect fibrosing interstitial lung disease on chest radiographs
por: Nishikiori, Hirotaka, et al.
Publicado: (2023)

Pirfenidone-induced Eosinophilic Pleurisy
por: Hase, Isano, et al.
Publicado: (2017)

Biphasic Effect of Pirfenidone on Angiogenesis
por: Gan, Donghao, et al.
Publicado: (2022)

Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
por: Jiang, Zhaosheng, et al.
Publicado: (2022)

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis
por: Molina-Molina, Maria, et al.
Publicado: (2022)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Role of pirfenidone in the management of pulmonary fibrosis
por: Meyer, Keith C, et al.
Publicado: (2017)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Systemic lymph node tuberculosis presenting with an aseptic psoas abscess caused by a paradoxical reaction after nine months of antituberculosis treatment: a case report
por: Yamada, Gen, et al.
Publicado: (2013)

Patterning nanofibrils through the templated growth of multiple modified amyloid peptides
por: Sakai, Hiroki, et al.
Publicado: (2016)

Interstitial lung disease associated with drug therapy
por: Camus, P, et al.
Publicado: (2004)

Reply to Kobayashi et al.: Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

A randomized controlled phase III trial protocol: perioperative pirfenidone therapy in patients with non-small cell lung cancer combined with idiopathic pulmonary fibrosis to confirm the preventative effect against postoperative acute exacerbation: the PIII-PEOPLE study (NEJ034)
por: Sakairi, Yuichi, et al.
Publicado: (2023)

The multifaceted role of pirfenidone and its novel targets
por: Macías-Barragán, José, et al.
Publicado: (2010)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Pirfenidone prevents acute kidney injury in the rat
por: Lima-Posada, Ixchel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j0i54vlcj9q0j0b8ap3hgc88kn